Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India

Impact · against what's priced in

Co-Diagnostics has reached a critical inflection point for its India strategy with the regulatory submission and successful clinical trial of its TB test. The expectation of a Q4 2026 launch in a market representing 25% of global TB cases provides a concrete near-term catalyst for revenue growth.

CODX+0.70

No priced-in read yet